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The COVID-19 global pandemic is accelerating investigations for effective vaccines and
repurposable validated therapeutics. Current data analyses strongly suggest that the disease mostly
affects the elderly population and patients with pre-existing conditions [1,2]. Considerably less attention
has been drawn towards the sex distribution of case fatalities, which is increasingly showing disparities
in mortality rates that varies geospatially, and along socioeconomic factors [3,4]. Reported death
estimates by sex vary greatly across contexts and population groups and may change over time.
In addition, social factors, such as testing and reporting bias in females, or differences in exposure
due to behavioral and risk differences, may play a role, e.g., due to comorbidities such as diabetes
or differences in societal and gender norms. While the observed male dominance in COVID-19
prevalence and mortality across most countries and cultures may suggest a role for biological
differences, the potential long-term impact of gender-related factors on mortality, especially in diverse
socioeconomic contextS, cannot be underestimated [5,6].
The role of immunological differences between females and males in the responses to SARS-CoV-2
infection appears to be justified. There is ample evidence that antiviral immunity differs between
the sexes [5]. These are caused by e.g., sex steroid hormone signaling (i.e., testosterone, estrogens,
and progesterone), genetics (e.g., immune function genes that escape X inactivation), and sex-specific
composition of the microbiome. Sex differences in immunosenescence and immune function not only
impact immunity to viruses, but to vaccines and immunotherapies, as well [5–7]. In the context of
SARS-CoV-2, these differences could impact susceptibility and initial response to the virus as well
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as choice of acute and long-term therapy of the COVID-19 pathology. In current and future trials
for COVID-19, sex as a biological variable should be factored in and understood, along with the
wider gendered implications of the COVID-19 crises, with the broader concept of how biological
factors intersect with gendered differences in exposure, transmission, and socio-economic means.
Consequently, the pandemic may not just lead to differences in disease susceptibility and manifestation
between men, women, and people with non-binary identities, but also exacerbate unequal access to
treatment and long-term vulnerabilities.
Given their non-negligible impact on health, sex and gender dimensions, along with other
socio-economic stratifiers, need to inform the design, conduct, analysis, and reporting of current
and forthcoming trials. Moving beyond sex-disaggregated data collection and including variables
such as disability, age, ethnicity, migration status, socioeconomic status, or geographic location,
will contribute to ensure health benefits from clinical trials for all. To better understand and respond to
the burden posed by COVID-19, both on health systems and different segments of human populations,
gender dimensions must be recognized as an intersecting component of wider structural inequalities [8].
Moreover, the COVID-19 pandemic is exposing, most acutely, the wider social inequalities that are
based on gendered social, cultural, and economic faultiness, whether it is leaving a majority of frontline
workers (in many contexts mostly women) without PPE, the disproportionate burden of unpaid care
on women, or gender-based violence perpetuated within the household, apart from the economic
devastations experienced by the poor and women in the poorest quintiles.
Equity in clinical trials starts with the consideration of both sex and gender dimensions in
studies on novel and repurposed drugs [9,10]. Biomedical AI-researchers can assist in this effort to
reconceptualize the human subgroups included for analysis, emphasizing the rigorous justification of
exclusion and avoiding assumptions that may have serious implications in terms of generalizability of
outcomes [9,11,12]. Ignoring aspects of sex and gender in data collection and analysis in clinical trials
has had detrimental consequences in the past. Eight out of ten drugs withdrawn from the US market in
the late 1990s had significantly more side effects in women than men, including fatal torsade-de-pointe
after excessive QT interval prolongation. The, yet to be accurately tested, proposed therapeutic regimen
of hydroxychloroquine and azithromycin for COVID-19 includes two QT-prolonging agents. Next to
potential sex differences in side effects, gender-related aspects have to be considered. For example,
despite the disproportionately high mortality of Ebola viral disease (EVD) among pregnant women,
the rVSV-ZEBOV vaccine clinical trials excluded pregnant women. This impacted access to critical
life-saving interventions during the subsequent Tenth EVD epidemic in DRC, when—due to lack of
evidence because of the beforementioned exclusions—pregnant and lactating women did not partake
in ring vaccination campaigns, until the decision was reversed 10 months later. This not only led to
unnecessary mortality of this vulnerable group, but severely impacted women’s right to decide on
research participation and community trust in the intervention, just as did the approval of Truvada
solely for cisgender males and transgender women [13,14].
The inclusion of sex and gender aspects in drug development and clinical trials is essential, not just
for a thorough understanding of efficacy and safety aspects of drugs, but also to ensure there is equity
in the distribution of innovation and discovery benefits of COVID-19 therapeutics and vaccines [3].
A group of clinicians, scientists and gender specialists working on global health, sex and gender
research and human rights are thus calling for action towards the inclusion of sex and gender, and other
socially relevant variables, into the methodology of COVID-19-related trials. Such an approach should
become a universal and manifest part of future clinical studies, to allow more personalized patient care
and contribute to universal health coverage.
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